Literature DB >> 22209446

Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck.

Chunying Shen1, Tingting Xu, Caiping Huang, Chaosu Hu, Shaoqin He.   

Abstract

Surgery is the main treatment modality for adenoid cystic carcinoma (ACC) originated from the head and neck. However, the extensive local infiltrative and perineural spread related to this malignancy often cause difficulty to achieve high tumor control. The aim of this study is to evaluate the efficacy of postoperative radiotherapy (RT) in ACC, and to identify prognostic variables associated with treatment outcomes. A retrospective review of 101 patients diagnosed with ACC in the head and neck region was performed. T stage distribution was T1, 25; T2, 35; T3, 18; and T4, 23 patients. All patients were grouped into two arms: surgery alone or combined with postoperative radiotherapy. The 5-year local-regional control (LRC), overall survival (OS) and disease-free survival (DFS) rates for all the patients were 70.5%, 91.7% and 63.2%, respectively. On univariant analysis, postoperative radiotherapy did improve the 5-year LRC and DFS compared to surgery alone (81.0% vs. 53.4%, p=0.0003 and 71.3% vs. 50.0%, p=0.0052, respectively). And patients with T1-T2 lesions achieved better treatment outcomes, whereas stage T3-T4 was associated with high local failure and poor disease-free survival. Furthermore, multivariate analysis revealed that the addition of radiotherapy and early lesions were both favorite predictors for local control and survival rates. The prognosis for ACC of the head and neck was excellent. Surgery combined with postoperative radiotherapy significantly reduced the local failure, and further improved disease-free survival. Nevertheless, the relatively high distant metastasis was an obstacle of curing the ACC patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22209446     DOI: 10.1016/j.oraloncology.2011.12.002

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  21 in total

1.  Concurrent chemoradiotherapy for locally advanced unresectable adenoid cystic carcinoma of head and neck: experience from a single institute.

Authors:  Monali Swain; Sarbani Ghosh-Laskar; Ashwini Budrukkar; Roshan Patil; Vedang Murthy; Tejpal Gupta; Naveen Mummudi; Kumar Prabhash; Amit Joshi; Vijay Maruti Patil; Vanita Naronha; Jai Prakash Agarwal
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-09       Impact factor: 2.503

Review 2.  Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck.

Authors:  T Subramaniam; P Lennon; J P O'Neill
Journal:  Ir J Med Sci       Date:  2015-04-17       Impact factor: 1.568

Review 3.  Adenoid cystic carcinoma: focus on heavy ion therapy and molecular imaging.

Authors:  Angelo Castello; Laura Olivari; Egesta Lopci
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

4.  Adenoid cystic carcinoma of head and neck: clinical predictors of outcome from a Canadian centre.

Authors:  J J Ko; J E Siever; D Hao; R Simpson; H Y Lau
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

5.  Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation.

Authors:  Safina Ali; Frank L Palmer; Nora Katabi; Nancy Lee; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Laryngoscope       Date:  2017-03-21       Impact factor: 3.325

6.  Clinical Outcomes and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck.

Authors:  Samuel Jang; Priyesh N Patel; Randall J Kimple; Timothy M McCulloch
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

7.  Controlling distant metastasis and surgical treatment are crucial for improving clinical outcome in uncommon head and neck malignancies, such as non-squamous cell carcinoma.

Authors:  Masashi Shiiba; Motoharu Unozawa; Morihiro Higo; Yukinao Kouzu; Atsushi Kasamatsu; Yosuke Sakamoto; Katsunori Ogawara; Katsuhiro Uzawa; Yuichi Takiguchi; Hideki Tanzawa
Journal:  Mol Clin Oncol       Date:  2014-05-08

8.  Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma.

Authors:  Emma Holliday; Onita Bhattasali; Merrill S Kies; Ehab Hanna; Adam S Garden; David I Rosenthal; William H Morrison; G Brandon Gunn; Jack Phan; X Ronald Zhu; Xiaodong Zhang; Steven J Frank
Journal:  Int J Part Ther       Date:  2016-03-24

9.  Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.

Authors:  E Hitre; B Budai; Z Takácsi-Nagy; G Rubovszky; E Tóth; É Remenár; C Polgár; I Láng
Journal:  Br J Cancer       Date:  2013-08-13       Impact factor: 7.640

10.  RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.

Authors:  Chun-Ye Zhang; Yang-Xing Zhao; Rong-Hui Xia; Jing Han; Bing-Shun Wang; Zhen Tian; Li-Zhen Wang; Yu-Hua Hu; Jiang Li
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.